Elizabeth Holmes might seek ‘mental disease’ defense at Theranos trial
By 
Aly McDevitt2020-09-15T16:29:00
Elizabeth Holmes, founder and CEO of now-defunct blood testing company Theranos, is exploring the idea of using “mental disease or defect” as part of her defense during her criminal fraud trial, which is set to begin in March.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleNeed to know: Elizabeth Holmes’s Theranos trial set to begin
Elizabeth Holmes’s legacy is on the line, as the long-awaited trial of the disgraced founder and CEO of blood-testing company Theranos begins Wednesday.
-
ArticleCarreyrou at TPRM: Theranos warning signs were there, but partners failed to spot them
John Carreyrou explained to third-party risk professionals at CW’s TPRM Virtual Summit that the mistakes made by Theranos’s business partners were entirely preventable—had they done their proper due diligence.
-
ArticleJohn Carreyrou at TPRM: How to spot a wolf in Steve Jobs’ clothing
John Carreyrou, the Wall Street Journal reporter who exposed Theranos and its founder Elizabeth Holmes as frauds, will be the keynote speaker on Day 2 of Compliance Week’s TPRM virtual conference Sept. 18.
More from Anti-Corruption
-
PremiumQ&A: Hellenic Bank CCO on progress made to fight corruption in Cyprus
Maria Aristidou Demetriou, chief compliance officer at Cyprus-based Hellenic Bank, spoke to Compliance Week about derisking in the Cypriot banking sector since Russian’s invasion of Ukraine and efforts to combat corruption, money laundering, and sanctions evasion.
-
News BriefEricsson completes DOJ-imposed compliance monitorship
Swedish telecommunications giant Ericsson announced the conclusion of the independent compliance monitorship imposed on the company following its 2019 settlement for violations of the Foreign Corrupt Practices Act.
-
PremiumEx-Albemarle CCO shares drivers behind data analytics success at CW2024
Former Albemarle CCO Andrew McBride explained at Compliance Week’s 2024 National Conference how he led the company’s compliance department to remediate the issues that led to apparent FCPA violations and how the team used data analytics to assess risks and implement compliance solutions.